Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.
The patent, EP3170904, "Compositions and methods for nucleic acid sequencing," is the second PacBio patent revoked by the EPO this year.
In a message posted on Twitter today, Oxford Nanopore said that revenues grew to $43.7 million last year, up from $17.8 million in 2017.
Under the non-exclusive agreement, Germany's Merck will globally distribute RevoluGen's Fire Monkey/Fire Flower kit for the extraction of high molecular weight DNA.
In Nature this week: athletes' gut microbiomes, nanopore metagenomic sequencing approach to diagnosing infectious diseases, and more.
At the company's annual user meeting in London, staff members previewed upgrades and changes that will result in higher throughput and accuracy at lower sequencing costs.
The direct-to-consumer firm offers whole-genome sequencing for under $1,000, along with specific reports on pharmacogenomics, health traits, and certain diseases.
The UW researchers have filed for a patent on the variable voltage method but have not disclosed commercialization plans.
The project plans to sequence 20,000 genomes in 2019, 50,000 by the end of 2020, and a total of 100,000 by the end of 2021 using Oxford Nanopore's PromethIon platform.
In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.